BACKGROUND AND PURPOSE: Higher plasma concentrations of the endogenous nitric oxides synthase inhibitor asymmetrical dimethylarginine (ADMA) are associated with increased risk of cardiovascular and cerebrovascular events and death, presumably by promoting endothelial dysfunction and subclinical atherosclerosis. We hypothesized that plasma ADMA concentrations are positively related to common carotid artery intimal-media thickness (CCA-IMT) and to internal carotid (ICA)/bulb IMT. METHODS: We investigated the cross-sectional relations of plasma ADMA with CCA-IMT and ICA/bulb IMT in 2958 Framingham Heart Study participants (mean age, 58 years; 55% women). RESULTS: In unadjusted analyses, ADMA was positively related to both CCA-IMT (beta per SD increment, 0.012; P<0.001) and ICA/bulb IMT (beta per SD increment, 0.059; P<0.001). In multivariable analyses (adjusting for age, sex, systolic blood pressure, antihypertensive treatment, smoking status, diabetes, BMI, total-to-HDL cholesterol ratio, log C-reactive protein, and serum creatinine), plasma ADMA was not associated with CCA-IMT (P=0.991), but remained significantly and positively related to ICA/bulb IMT (beta per SD increment, 0.0246; P=0.002). CONCLUSIONS: In our large community-based sample, we observed that higher plasma ADMA concentrations were associated with greater ICA/bulb IMT, but not with CCA-IMT. These data are consistent with the notion that ADMA promotes subclinical atherosclerosis in a site-specific manner, with a greater proatherogenic influence at known vulnerable sites in the arterial tree.
BACKGROUND AND PURPOSE: Higher plasma concentrations of the endogenous nitric oxides synthase inhibitor asymmetrical dimethylarginine (ADMA) are associated with increased risk of cardiovascular and cerebrovascular events and death, presumably by promoting endothelial dysfunction and subclinical atherosclerosis. We hypothesized that plasma ADMA concentrations are positively related to common carotid artery intimal-media thickness (CCA-IMT) and to internal carotid (ICA)/bulb IMT. METHODS: We investigated the cross-sectional relations of plasma ADMA with CCA-IMT and ICA/bulb IMT in 2958 Framingham Heart Study participants (mean age, 58 years; 55% women). RESULTS: In unadjusted analyses, ADMA was positively related to both CCA-IMT (beta per SD increment, 0.012; P<0.001) and ICA/bulb IMT (beta per SD increment, 0.059; P<0.001). In multivariable analyses (adjusting for age, sex, systolic blood pressure, antihypertensive treatment, smoking status, diabetes, BMI, total-to-HDL cholesterol ratio, log C-reactive protein, and serum creatinine), plasma ADMA was not associated with CCA-IMT (P=0.991), but remained significantly and positively related to ICA/bulb IMT (beta per SD increment, 0.0246; P=0.002). CONCLUSIONS: In our large community-based sample, we observed that higher plasma ADMA concentrations were associated with greater ICA/bulb IMT, but not with CCA-IMT. These data are consistent with the notion that ADMA promotes subclinical atherosclerosis in a site-specific manner, with a greater proatherogenic influence at known vulnerable sites in the arterial tree.
Authors: C Zoccali; S Bode-Böger; F Mallamaci; F Benedetto; G Tripepi; L Malatino; A Cataliotti; I Bellanuova; I Fermo; J Frölich; R Böger Journal: Lancet Date: 2001 Dec 22-29 Impact factor: 79.321
Authors: K Yogo; H Shimokawa; H Funakoshi; T Kandabashi; K Miyata; S Okamoto; K Egashira; P Huang; T Akaike; A Takeshita Journal: Arterioscler Thromb Vasc Biol Date: 2000-11 Impact factor: 8.311
Authors: Julio A Chirinos; Robert David; J Alexander Bralley; Humberto Zea-Díaz; Edgar Muñoz-Atahualpa; Fernando Corrales-Medina; Carolina Cuba-Bustinza; Julio Chirinos-Pacheco; Josefina Medina-Lezama Journal: Hypertension Date: 2008-10-13 Impact factor: 10.190
Authors: Jan T Kielstein; Burcu Impraim; Solveig Simmel; Stefanie M Bode-Böger; Dimitrios Tsikas; Jürgen C Frölich; Marius M Hoeper; Hermann Haller; Danilo Fliser Journal: Circulation Date: 2003-12-08 Impact factor: 29.690
Authors: Caroline S Fox; L Adrienne Cupples; Irmarie Chazaro; Joseph F Polak; Philip A Wolf; Ralph B D'Agostino; Jose M Ordovas; Christopher J O'Donnell Journal: Am J Hum Genet Date: 2004-01-16 Impact factor: 11.025
Authors: R J Nijveldt; T Teerlink; B Van Der Hoven; M P C Siroen; D J Kuik; J A Rauwerda; P A M van Leeuwen Journal: Clin Nutr Date: 2003-02 Impact factor: 7.324
Authors: Vinod Achan; Michael Broadhead; Mohammed Malaki; Guy Whitley; James Leiper; Raymond MacAllister; Patrick Vallance Journal: Arterioscler Thromb Vasc Biol Date: 2003-06-12 Impact factor: 8.311
Authors: Bob Siegerink; Renke Maas; Carla Y Vossen; Edzard Schwedhelm; Wolfgang Koenig; Rainer Böger; Dietrich Rothenbacher; Hermann Brenner; Lutz P Breitling Journal: Clin Res Cardiol Date: 2012-10-17 Impact factor: 5.460
Authors: Martin Bahls; Nele Friedrich; Dorothee Atzler; Stephan B Felix; Matthias A Nauck; Rainer H Böger; Henry Völzke; Edzard Schwedhelm; Marcus Dörr Journal: PLoS One Date: 2015-06-22 Impact factor: 3.240
Authors: Frank Leypoldt; Chi-Un Choe; Mathias Gelderblom; Eike-Christin von Leitner; Dorothee Atzler; Edzard Schwedhelm; Christian Gerloff; Karsten Sydow; Rainer H Böger; Tim Magnus Journal: PLoS One Date: 2009-10-07 Impact factor: 3.240
Authors: Shufen Chen; Na Li; Milani Deb-Chatterji; Qiang Dong; Jan T Kielstein; Karin Weissenborn; Hans Worthmann Journal: Int J Mol Sci Date: 2012-11-28 Impact factor: 5.923